Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Feb 15, 2025; 17(2): 100094
Published online Feb 15, 2025. doi: 10.4251/wjgo.v17.i2.100094
Published online Feb 15, 2025. doi: 10.4251/wjgo.v17.i2.100094
Nucleotide-binding domain, leucine-rich repeat, and pyrin domain-containing protein 3 inflammasome: From action mechanism to therapeutic target in clinical trials
Chun-Ye Zhang, Bond Life Sciences Center, University of Missouri, Columbia, MO 65212, United States
Shuai Liu, The First Affiliated Hospital, Zhejiang University, Hangzhou 310006, Zhejiang Province, China
Yu-Xiang Sui, School of Life Science, Shanxi Normal University, Linfen 041004, Shanxi Province, China
Ming Yang, Department of Surgery, University of Connecticut, School of Medicine, Farmington, CT 06030, United States
Author contributions: Zhang CY, Liu S, Sui YX, and Yang M designed the study, collected the data and wrote, revised, and finalized the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ming Yang, PhD, Assistant Professor, Department of Surgery, University of Connecticut, School of Medicine, 263 Farmington Avenue, Farmington, CT 06030, United States. minyang@uchc.edu
Received: August 7, 2024
Revised: October 23, 2024
Accepted: November 5, 2024
Published online: February 15, 2025
Processing time: 164 Days and 6.1 Hours
Revised: October 23, 2024
Accepted: November 5, 2024
Published online: February 15, 2025
Processing time: 164 Days and 6.1 Hours
Core Tip
Core Tip: The nucleotide-binding domain, leucine-rich repeat, and pyrin domain-containing protein 3 (NLRP3) inflammasome plays a pivotal role in many diseases such as inflammatory diseases, metabolic disorders, and neurodegenerative diseases. The investigation of NLRP3 as a therapeutic target is involved in many preclinical studies and clinical trials. Among these studies, NLRP3 inhibitors and downstream interleukin-1 inhibitors attract wide-spectrum attention. In addition, NLRP3 activation also impacts cancer development and immunotherapy, serving as a potential therapeutic target for cancer treatment.